Hospital Infection Therapeutics Market to grow at a CAGR of 4.98% from 2022 to 2027, antibiotics to be a major segment for the growth of the market - Technavio
The global hospital infection therapeutics market is projected to grow by USD 3,106.6 million from 2022 to 2027, with a CAGR of 4.98%. The market is segmented by drug class (antibiotics, antifungals, antivirals) and infection type (respiratory, surgical, bloodstream, gastrointestinal, urinary). North America is expected to contribute 36% to this growth, driven by increasing chronic disease incidence and higher healthcare spending. Key market players include Abbott, Pfizer, and AstraZeneca, while challenges include stringent regulations affecting R&D.
- Projected growth of USD 3,106.6 million from 2022 to 2027.
- CAGR of 4.98% indicates healthy market expansion.
- North America contributing 36% of market growth.
- Increasing incidence of respiratory disorders driving demand.
- Diverse segments in antibiotics class are expected to boost market.
- Stringent regulations increasing R&D costs and market entry barriers.
- Only 1 in 5,000 new drugs reaches the market, indicating high risk.
For more insights on the historic market data (2017 to 2021) and forecast market size (2023 to 2027) - Request a sample report
What's New?
- Special coverage on the
Russia -Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession - Global competitiveness and key competitor positions
- Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - buy the report!
Hospital Infection Therapeutics Market - Segmentation Assessment
Segment Overview
- The market share growth by the antibiotics drugs segment will be significant for the growth of the global hospital infection therapeutics market during the forecast period. Antibiotics are therapeutic agents used to prevent and treat infections caused by bacteria and other susceptible microorganisms. The increasing prevalence of infectious diseases globally drives the growth of the segment during the forecast period. There are two types of antibiotics, namely broad-spectrum and narrow-spectrum antibiotics. Broad-spectrum antibiotics are effective against a wide range of microorganisms whereas narrow-spectrum antibiotics are active against a few certain groups of bacteria. Broad-spectrum antibiotics include amoxicillin, levofloxacin, gatifloxacin, streptomycin, tetracycline, and chloramphenicol. Narrow-spectrum antibiotics that are commonly used include azithromycin, clarithromycin, clindamycin, erythromycin, and vancomycin. Hence, these factors are expected to drive the growth of the antibiotic drug segment of the global hospital infection therapeutics market during the forecast period.
Geography Overview
By geography, the global hospital infection therapeutics market is segmented into
North America is estimated to account for36% of the growth of the global hospital infections therapeutics market during the forecast period. The growth of the market in the region can be attributed to factors such as the increasing incidence of chronic diseases, growth in healthcare expenditure, and the rising preference for therapeutics over surgical procedures. Other factors include the growing focus of pharmaceutical and biotechnology companies on R&D, the increasing geriatric population, and the presence of global and regional vendors.
Hospital Infection Therapeutics Market – Vendor Analysis
The global hospital infection therapeutics market is fragmented with the presence of various global and regional vendors. Abbott Laboratories, AbbVie Inc.,
Insights on the market contribution of various segments including country and region wise, historic market data (2017 to 2021), and forecast market size (2023 to 2027) - Download a Sample Report
Hospital Infection Therapeutics Market – Market Dynamics
Key factor driving market growth
The increase in the incidence and prevalence of respiratory disorders is driving the hospital infection therapeutics market growth significantly. Among other hospital infectious diseases, respiratory diseases are one of the main causes of mortality worldwide. There is a rise in the prevalence of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory infections. In the US, more than 534,242 deaths of men and women were due to chronic respiratory diseases. Thus, the rise in the incidence and prevalence of respiratory disorders will drive the growth of the global hospital-acquired infections therapeutics market during the forecast period.
Leading trends influencing the market
The increase in hospital visits is a major trend influencing the hospital infection therapeutics market growth. With the rise in chronic diseases around the world, the number of visits to hospitals is also increasing. Hospitals are a primary source of infections, which results in a rise in morbidity and mortality in hospitalized patients. The increasing incidence of hospital infectious diseases has created a significant social and economic burden on the healthcare system. Furthermore, the aging population is increasing globally. This will increase the demand for blood culture tests performed on patients, which will support the growth of the hospital infections therapeutics market during the forecast period.
Major challenges hindering the market growth
Stringent regulations may hinder the hospital infection therapeutics market growth during the forecast period. Vendors should adhere to stringent regulations enforced by regulatory authorities such as the
Insights on market drivers, trends, & challenges, historic period(2017 to 2021), and forecast period(2023 to 2027)- Request a sample report!
What are the key data covered in this Hospital Infection Therapeutics Market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the hospital infection therapeutics market between 2023 and 2027
- Precise estimation of the size of the hospital infection therapeutics market and its contribution to the market with a focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the hospital infection therapeutics market across
North America ,Europe ,Asia , and the Rest of the World (ROW) - A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of hospital infection therapeutics market vendors
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Related Reports:
The pruritus therapeutic market size is expected to increase by USD 4.01 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of
The aspergillosis drugs market size has the potential to grow by USD 658.48 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period. The development of therapeutics with novel mechanisms that have better tolerance levels and efficacy will lead to a strong pipeline.
Hospital Infection Therapeutics Market Scope | |
Report Coverage | Details |
Base year | 2022 |
Historic period | 2017-2021 |
Forecast period | 2023-2027 |
Growth momentum & CAGR | Accelerate at a CAGR of |
Market growth 2023-2027 | |
Market structure | Fragmented |
YoY growth 2022-2023 (%) | 4.75 |
Regional analysis | |
Performing market contribution | |
Key countries | US, |
Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled | Abbott Laboratories, AbbVie Inc., |
Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio Health Care market reports
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global hospital infection therapeutics market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global hospital infection therapeutics market 2017 - 2021 ($ million)
- 4.2 Drug Class Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)
- 4.3 Type Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Drug Class
- 6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
- 6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class
- 6.3 Antibiotics drugs - Market size and forecast 2022-2027
- Exhibit 34: Chart on Antibiotics drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Antibiotics drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Antibiotics drugs - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Antibiotics drugs - Year-over-year growth 2022-2027 (%)
- 6.4 Antifungal drugs - Market size and forecast 2022-2027
- Exhibit 38: Chart on Antifungal drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Antifungal drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Antifungal drugs - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Antifungal drugs - Year-over-year growth 2022-2027 (%)
- 6.5 Antiviral drugs - Market size and forecast 2022-2027
- Exhibit 42: Chart on Antiviral drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Antiviral drugs - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Antiviral drugs - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Antiviral drugs - Year-over-year growth 2022-2027 (%)
- 6.6 Market opportunity by Drug Class
- Exhibit 46: Market opportunity by Drug Class ($ million)
7 Market Segmentation by Type
- 7.1 Market segments
- Exhibit 47: Chart on Type - Market share 2022-2027 (%)
- Exhibit 48: Data Table on Type - Market share 2022-2027 (%)
- 7.2 Comparison by Type
- Exhibit 49: Chart on Comparison by Type
- Exhibit 50: Data Table on Comparison by Type
- 7.3 Respiratory tract infections - Market size and forecast 2022-2027
- Exhibit 51: Chart on Respiratory tract infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Respiratory tract infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Respiratory tract infections - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Respiratory tract infections - Year-over-year growth 2022-2027 (%)
- 7.4 Surgical site infections - Market size and forecast 2022-2027
- Exhibit 55: Chart on Surgical site infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 56: Data Table on Surgical site infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Chart on Surgical site infections - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Surgical site infections - Year-over-year growth 2022-2027 (%)
- 7.5 Bloodstream infections - Market size and forecast 2022-2027
- Exhibit 59: Chart on Bloodstream infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 60: Data Table on Bloodstream infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Chart on Bloodstream infections - Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Bloodstream infections - Year-over-year growth 2022-2027 (%)
- 7.6 Gastrointestinal infections - Market size and forecast 2022-2027
- Exhibit 63: Chart on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on Gastrointestinal infections - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Gastrointestinal infections - Year-over-year growth 2022-2027 (%)
- 7.7 Urinary tract infections - Market size and forecast 2022-2027
- Exhibit 67: Chart on Urinary tract infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Urinary tract infections - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Urinary tract infections - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Urinary tract infections - Year-over-year growth 2022-2027 (%)
- 7.8 Market opportunity by Type
- Exhibit 71: Market opportunity by Type ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 73: Chart on Market share by geography 2022-2027 (%)
- Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 75: Chart on Geographic comparison
- Exhibit 76: Data Table on Geographic comparison
- 9.3
North America - Market size and forecast 2022-2027 - Exhibit 77: Chart on
North America - Market size and forecast 2022-2027 ($ million) - Exhibit 78: Data Table on
North America - Market size and forecast 2022-2027 ($ million) - Exhibit 79: Chart on
North America - Year-over-year growth 2022-2027 (%) - Exhibit 80: Data Table on
North America - Year-over-year growth 2022-2027 (%)
- 9.4
Europe - Market size and forecast 2022-2027 - Exhibit 81: Chart on
Europe - Market size and forecast 2022-2027 ($ million) - Exhibit 82: Data Table on
Europe - Market size and forecast 2022-2027 ($ million) - Exhibit 83: Chart on
Europe - Year-over-year growth 2022-2027 (%) - Exhibit 84: Data Table on
Europe - Year-over-year growth 2022-2027 (%)
- 9.5
Asia - Market size and forecast 2022-2027 - Exhibit 85: Chart on
Asia - Market size and forecast 2022-2027 ($ million) - Exhibit 86: Data Table on
Asia - Market size and forecast 2022-2027 ($ million) - Exhibit 87: Chart on
Asia - Year-over-year growth 2022-2027 (%) - Exhibit 88: Data Table on
Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8
Germany - Market size and forecast 2022-2027 - Exhibit 97: Chart on
Germany - Market size and forecast 2022-2027 ($ million) - Exhibit 98: Data Table on
Germany - Market size and forecast 2022-2027 ($ million) - Exhibit 99: Chart on
Germany - Year-over-year growth 2022-2027 (%) - Exhibit 100: Data Table on
Germany - Year-over-year growth 2022-2027 (%)
- 9.9
China - Market size and forecast 2022-2027 - Exhibit 101: Chart on
China - Market size and forecast 2022-2027 ($ million) - Exhibit 102: Data Table on
China - Market size and forecast 2022-2027 ($ million) - Exhibit 103: Chart on
China - Year-over-year growth 2022-2027 (%) - Exhibit 104: Data Table on
China - Year-over-year growth 2022-2027 (%)
- 9.10
France - Market size and forecast 2022-2027 - Exhibit 105: Chart on
France - Market size and forecast 2022-2027 ($ million) - Exhibit 106: Data Table on
France - Market size and forecast 2022-2027 ($ million) - Exhibit 107: Chart on
France - Year-over-year growth 2022-2027 (%) - Exhibit 108: Data Table on
France - Year-over-year growth 2022-2027 (%)
- 9.11
UK - Market size and forecast 2022-2027 - Exhibit 109: Chart on
UK - Market size and forecast 2022-2027 ($ million) - Exhibit 110: Data Table on
UK - Market size and forecast 2022-2027 ($ million) - Exhibit 111: Chart on
UK - Year-over-year growth 2022-2027 (%) - Exhibit 112: Data Table on
UK - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 113: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 114: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 116: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 117: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 118: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 119: Matrix on vendor position and classification
- 12.3 Abbott Laboratories
- Exhibit 120: Abbott Laboratories - Overview
- Exhibit 121: Abbott Laboratories - Business segments
- Exhibit 122: Abbott Laboratories - Key news
- Exhibit 123: Abbott Laboratories - Key offerings
- Exhibit 124: Abbott Laboratories - Segment focus
- 12.4 AbbVie Inc.
- Exhibit 125: AbbVie Inc. - Overview
- Exhibit 126: AbbVie Inc. - Product / Service
- Exhibit 127: AbbVie Inc. - Key news
- Exhibit 128: AbbVie Inc. - Key offerings
- 12.5 Achilles Therapeutics plc
- Exhibit 129:
Achilles Therapeutics plc - Overview - Exhibit 130:
Achilles Therapeutics plc - Product / Service - Exhibit 131:
Achilles Therapeutics plc - Key offerings
- 12.6 AstraZeneca Plc
- Exhibit 132: AstraZeneca Plc - Overview
- Exhibit 133: AstraZeneca Plc - Product / Service
- Exhibit 134: AstraZeneca Plc - Key news
- Exhibit 135: AstraZeneca Plc - Key offerings
- 12.7 Bayer AG
- Exhibit 136: Bayer AG - Overview
- Exhibit 137: Bayer AG - Business segments
- Exhibit 138: Bayer AG - Key news
- Exhibit 139: Bayer AG - Key offerings
- Exhibit 140: Bayer AG - Segment focus
- 12.8 Bristol Myers Squibb Co.
- Exhibit 141: Bristol Myers Squibb Co. - Overview
- Exhibit 142: Bristol Myers Squibb Co. - Product / Service
- Exhibit 143: Bristol Myers Squibb Co. - Key news
- Exhibit 144: Bristol Myers Squibb Co. - Key offerings
- 12.9 F. Hoffmann La Roche Ltd.
- Exhibit 145: F.
Hoffmann La Roche Ltd. - Overview - Exhibit 146: F.
Hoffmann La Roche Ltd. - Business segments - Exhibit 147: F.
Hoffmann La Roche Ltd. - Key news - Exhibit 148: F.
Hoffmann La Roche Ltd. - Key offerings - Exhibit 149: F.
Hoffmann La Roche Ltd. - Segment focus
- 12.10 Gilead Sciences Inc.
- Exhibit 150: Gilead Sciences Inc. - Overview
- Exhibit 151: Gilead Sciences Inc. - Product / Service
- Exhibit 152: Gilead Sciences Inc. - Key news
- Exhibit 153: Gilead Sciences Inc. - Key offerings
- 12.11 GlaxoSmithKline Plc
- Exhibit 154: GlaxoSmithKline Plc - Overview
- Exhibit 155: GlaxoSmithKline Plc - Business segments
- Exhibit 156: GlaxoSmithKline Plc - Key offerings
- Exhibit 157: GlaxoSmithKline Plc - Segment focus
- 12.12 Johnson and Johnson
- Exhibit 158: Johnson and Johnson - Overview
- Exhibit 159: Johnson and Johnson - Business segments
- Exhibit 160: Johnson and Johnson - Key news
- Exhibit 161: Johnson and Johnson - Key offerings
- Exhibit 162: Johnson and Johnson - Segment focus
- 12.13 Merck and Co. Inc.
- Exhibit 163: Merck and Co. Inc. - Overview
- Exhibit 164: Merck and Co. Inc. - Business segments
- Exhibit 165: Merck and Co. Inc. - Key news
- Exhibit 166: Merck and Co. Inc. - Key offerings
- Exhibit 167: Merck and Co. Inc. - Segment focus
- 12.14 Novartis AG
- Exhibit 168: Novartis AG - Overview
- Exhibit 169: Novartis AG - Business segments
- Exhibit 170: Novartis AG - Key offerings
- Exhibit 171: Novartis AG - Segment focus
- 12.15 Pfizer Inc.
- Exhibit 172: Pfizer Inc. - Overview
- Exhibit 173: Pfizer Inc. - Product / Service
- Exhibit 174: Pfizer Inc. - Key news
- Exhibit 175: Pfizer Inc. - Key offerings
- 12.16
Sanofi SA - Exhibit 176:
Sanofi SA - Overview - Exhibit 177:
Sanofi SA - Business segments - Exhibit 178:
Sanofi SA - Key news - Exhibit 179:
Sanofi SA - Key offerings - Exhibit 180:
Sanofi SA - Segment focus
- 12.17 Viatris Inc.
- Exhibit 181: Viatris Inc. - Overview
- Exhibit 182: Viatris Inc. - Business segments
- Exhibit 183: Viatris Inc. - Key offerings
- Exhibit 184: Viatris Inc. - Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 185: Inclusions checklist
- Exhibit 186: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 187: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 188: Research methodology
- Exhibit 189: Validation techniques employed for market sizing
- Exhibit 190: Information sources
- 13.5 List of abbreviations
- Exhibit 191: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Media & Marketing Executive
US: +1 844 364 1100
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-to-grow-at-a-cagr-of-4-98-from-2022-to-2027--antibiotics-to-be-a-major-segment-for-the-growth-of-the-market---technavio-301771847.html
SOURCE Technavio
FAQ
What is the forecast growth of the hospital infection therapeutics market?
What is the CAGR for the hospital infection therapeutics market?
How much of the growth will North America contribute in this market?
Who are the major vendors in the hospital infection therapeutics market?
What challenges does the hospital infection therapeutics market face?
